After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
See which stocks are posting big moves after the bell.Market Insiderread more
"I'd love to say that the optimistic universe is most likely to prevail, but the talking heads talk endlessly about how a recession is inevitable," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Read the fine print in your Apple Card contract — one clause means you give up your right to be heard in court.Technologyread more
Federal Reserve members worried over future growth are highly concerned about the U.S.-China tariff battleThe Fedread more
President Donald Trump signed a memorandum on Wednesday to automatically cancel the student loan debt of disabled veterans. More than 25,000 service members will have their...Personal Financeread more
President Trump and Apple CEO Tim Cook have had a rocky relationship in recent years, but Trump is now complimenting the executive publicly.Technologyread more
Shares of Zogenix zoomed 180 percent higher in midday trading Friday after positive results from a study on its treatment of a rare form of epilepsy.
At one point in early premarket trading where volume is light the shares had tripled.
The biotechnology company reported significant results in a Phase 3 trial of its drug ZX008, which is a treatment for Dravet syndrome. Zogenix stock traded at $12.88 per share at market close on Thursday, according to FactSet. It was trading near $36 in the early afternoon.
"We remain on track to submit applications for regulatory approvals in the U.S. and Europe in the second half of 2018," Zogenix CEO Stephen Farr said in a statement.
Farr said his company was "extremely pleased" with the treatment's results in children and young adults. In total, 119 patients participated in the ZX008 trial. One of the three dosage groups saw an average 64 percent reduction in monthly convulsive seizures compared to placebo treatments.
The drug also saw "clinically meaningful reductions" in the frequency of seizures, Zogenix said, as well as an increase in time between seizures.
GW Pharmaceuticals stock fell over 8 percent Friday as investors feared competition from Zogenix. GW Pharmaceuticals manufactures cannabis-based treatment Epidiolex, which is in Phase 3 trials to treat Dravet syndrome.
Based in Emeryville, California, Zogenix expects results from a second trial in the first half of next year.
Correction: An earlier version misspelled Dravet.